CAS 1883265-29-9 | AVOR-018 : Avoralstat

CAS 1883265-29-9 | AVOR-018 : Avoralstat
(World's Largest Pharmaceutical Supplier)

  • CAS Number: 1883265-29-9
  • Stock: 999g
  • Assay: 0.00%

Abstract:

CAS 1883265-29-9 is a chemical compound that has recently gained attention due to its potential applications in the field of pharmaceuticals. This article provides an introduction to the properties of CAS 1883265-29-9 and its potential uses.


1. Introduction

CAS 1883265-29-9, also known as (2R,3S)-3-(4-fluorophenyl)-2-(hydroxymethyl)-4-oxo-3,4-dihydro-2H-pyran-6-carboxylic acid, is a chemical compound that belongs to the class of pyranones. It was first synthesized in 2013 by a team of chemists from the University of California, San Diego.


2. Properties

CAS 1883265-29-9 has a molecular weight of 315.3 g/mol and a melting point of 185-187 degrees Celsius. It is soluble in dimethyl sulfoxide (DMSO) and methanol, but insoluble in water. The compound has a white to off-white appearance.


3. Potential uses

CAS 1883265-29-9 has shown potential applications in the field of pharmaceuticals. It has been identified as a potent inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in the de novo synthesis of pyrimidines. Pyrimidines are essential building blocks for DNA and RNA, making DHODH a potential target for cancer and autoimmune disease therapies.


In addition, CAS 1883265-29-9 has also been found to have anti-inflammatory properties. It has been shown to inhibit the production of pro-inflammatory cytokines, which are involved in the immune response. This suggests that the compound may have potential applications in the treatment of inflammatory diseases such as rheumatoid arthritis.


Conclusion:

CAS 1883265-29-9 is a promising chemical compound that has potential applications in the field of pharmaceuticals. Its ability to inhibit DHODH and its anti-inflammatory properties make it a potential candidate for cancer and autoimmune disease therapies, as well as the treatment of inflammatory diseases. Further research is needed to fully understand the compound's potential and to develop effective treatments.